Performing safety risk assessments that are based on perturbations in cellular signaling pathways rather than adverse effects in animal studies requires the use of multiple tools and approaches ([@kfy245-B24]). Ensuring risk assessments are protective for all relevant health effects means that pathways associated with cellular stress responses as well as with specific targets such as nuclear receptors need to be considered ([@kfy245-B28]). A Molecular Initiating Event (MIE), is the initial interaction between a molecule and a biomolecule or biosystem that can be causally linked to an outcome *via* a pathway ([@kfy245-B4]). Reporter gene assays are useful tools in discovering or confirming the MIEs that may be associated with a specific chemical exposure, and therefore have an important role in the development of human-relevant mechanistic toxicological risk assessments. One example of a receptor-mediated MIE is androgen receptor (AR) antagonism. We have previously described how a non-animal risk assessment for anti-androgenic effects could be developed and the central importance of the AR to this strategy ([@kfy245-B18]).

A number of tools are already available to characterize the effects of chemical exposure on many of the MIEs relevant for perturbation of the hypothalamus-pituitary-testicular (HPT) axis, including AR (ant)agonism. However, not all the tools needed to make the link between *in vitro* anti-androgenic activity and an adverse health effect in humans are available. These include higher tier *in vitro* tools able to distinguish endocrine activity from adversity and computational models describing the human HPT axis. Such higher tier tools may not be necessary where there is a low probability of exposure and effect concentrations overlapping. This principle has already been employed to compare high-throughput exposure data and bioactivity information from the ToxCast program ([@kfy245-B45]), and such *in vitro* to *in vivo* extrapolation approaches are considered robust enough to be used for testing prioritization ([@kfy245-B43]). Comparison of AC~50~ or IC~50~ values from human-relevant *in vitro* assays with human plasma exposures is therefore gaining popularity as a method of performing mechanistic human safety risk assessments. In addition to broad screening using multiple *in vitro* assays representing different modes of action, this approach has also been used specifically for endocrine activity using data for estrogen receptor agonism and androgen receptor antagonism ([@kfy245-B16]). One question facing toxicologists performing risk assessments based on new approaches is whether extrapolating from *in vitro* AC~50~ or IC~50~ values is protective of human health, and what 'margin of exposure' is sufficient between the *in vitro* point of departure and the predicted or measured plasma exposure level to assure human safety? One way to address these questions is to put margins of exposure derived from *in vitro* only risk assessments into context against margins of exposure for comparator substances with the same mode of action. One method that has been proposed for estrogen agonists is to calculate the exposure: activity ratios (EARs) for test substances, and directly compare these with the EAR of a comparator with a history of dietary exposure ([@kfy245-B11][@kfy245-B10]). In that approach for estrogen agonists, the phytoestrogen genistein was selected as the comparator. An EAR for genistein was calculated by dividing the human plasma concentration of genistein at steady state (determined from several studies examining plasma exposure following consumption of soy products) by a measure of *in vitro* activity for the estrogen signaling pathway. Based on the assumption that normal dietary exposure to phytoestrogens is low risk, the EARs for genistein were then compared with EARs calculated for other estrogen agonists to provide 'relative estrogenic activity exposure quotients.' Such an approach shows promise because it considers exposure alongside bioactivity data, and because it is focuses on the assessment of human safety risk rather than an attempt to replicate the results of rodent toxicology studies ([@kfy245-B17]; [@kfy245-B24]). We therefore applied similar techniques to investigate the utility of this approach for anti-androgenic materials. To provide the measure of anti-androgenic activity we selected the AR CALUX^®^ assay ([@kfy245-B38]) as a human relevant and highly specific reporter gene assay for AR agonists and antagonists ([@kfy245-B40]).

The objectives of this work were to: Test a number of dietary components in the AR CALUX^®^ assay to identify a comparator that could be used to help put the exposure and activity of anti-androgens into context.Estimate plasma exposures in humans to the dietary comparator to allow EARs for other anti-androgens to be put into context.Use a case study to investigate whether this approach could be used to arrive at a safety decision for perturbations in AR signaling for an ingredient in a consumer product without the need to generate animal data.

MATERIALS AND METHODS: AR CALUX^®^ ASSAY
========================================

Test and reference substances
-----------------------------

Common dietary constituents tested in the AR CALUX^®^ assay were genistein, resveratrol, diindolylmethane (DIM), quercetin, and rutin. Case study ingredients were andrographolide (AG) and bakuchiol. Reference substances were dihydrotestosterone (DHT), flutamide, and 2-hydroxyflutamide. All test or reference substances were obtained from Sigma, with the exception of DHT which was either prepared as a concentration series in DMSO by Bio Detection Systems B.V. (BDS, Amsterdam, The Netherlands) using DHT supplied by Steraloids Inc. (purity \> 98%) or supplied by Sigma (purity ≥ 99%) and prepared as a concentration series in DMSO in-house. The purity of all test substances was ≥ 95%.

Cell culture
------------

AR CALUX^®^ cells were obtained and used under license from BDS. The cells were cultured in growth medium comprised of Dulbecco's Modified Eagle Medium (DMEM/F12, Thermofisher 31331028) containing 7.5% heat inactivated fetal calf serum (FCS), 1% non-essential amino acid solution (NEAA, Sigma), and 10 000 U/ml penicillin/10 000 µg/ml streptomycin (Sigma). During subculture, once per week 200 µg/ml G418 (gentamycin, Sigma) solution was added to the medium. The assay was performed in Phenol Red-free DMEM/F12 medium (Thermofisher 21041025) containing 5% charcoal stripped FCS (Gibco), 1% NEAA, and 10 000 U/ml Penicillin/10 000 µg/ml streptomycin.

AR CALUX^®^ assay method
------------------------

The assay was conducted in a GLP compliant laboratory using test methods based on previously reported procedures ([@kfy245-B38]). On Day 1 of the assay, cells were seeded in white, clear-bottomed 96-well plates at a density of 1 × 10^5^ cells/ml in assay medium, 100 µl of cell suspension per well. Plates were incubated for at least 16 h (37°C 5% CO~2~). On Day 2, wells were checked to ensure 50%--90% confluency. Medium was removed and 200 µl of the test substance or reference standard in assay medium was added to triplicate wells. All test/reference substances were tested in both the agonism and antagonism assay, with the exception of flutamide and 2-hydroxyflutamide which were only tested in the antagonism assay. In the agonism assay, each plate included a DHT concentration series (1 × 10^−12^ to 1 × 10^−7^ M) for quality control purposes as well as the concentration range of the test substance. The concentration range for each test substance was determined by performing a cytotoxicity evaluation to ensure that the highest concentration tested did not cause any changes in cell number or morphology, and descending concentrations were set at half log intervals or closer if required to investigate a steep dose-response. Cell number was assessed using the Sigma Cell Counting Kit 8, and morphology was evaluated by light microscopy. For the antagonism assay, the medium was supplemented with a non-saturating level of DHT approximating to the EC~50~ of this ligand (3 × 10^−10^ M). Each plate included a flutamide concentration series (1 × 10^−9^ to 1 × 10^−5^ M) for quality control purposes as well as the concentration range of the test substance. Plates were incubated for 24 h. On Day 3, the luciferase assay was performed, using the ONE-Glo Luciferase Assay System (Promega). Luminescence was measured in a Tecan Safire plate reader. In cases where antagonism was observed (determined as at least a 20% decrease in relative induction of the test substance at a non-cytotoxic concentration) a specificity control assay was performed to ensure the decrease in relative induction was not due to a non-specific effect on eg general cellular health. This was done by assessing whether the decrease in relative induction was reversible in a saturating concentration of the ligand (DHT). Therefore, in the specificity control assay each plate included the concentration range of the test substance in medium containing the non-saturating level of DHT, the concentration range of the test substance in a saturating level of DHT (3 × 10^−8^ M), which approximates to the EC~50~ × 100. A single concentration of flutamide (1 × 10^−5^ M) in medium containing each level of DHT was also included to serve as a reference. Each experiment comprised at least 3 independent replicates.

Data interpretation
-------------------

Correction for background luminescence was performed by subtracting the relative luminescence of the control (DMSO only) wells for each plate. The results were expressed relative to the reference standard, which was DHT for the agonism assay (luciferase expression at highest DHT concentration =100%) and Flutamide for the antagonism assay (luciferase expression at highest Flutamide concentration = 0%). Data were analyzed using GraphPad Prism and plotted as mean values ± SEM. Dose-response modeling was performed on log transformed data using the nonlinear variable slope (four parameters) equation (four-parameter logistic curve) in GraphPad for either stimulation (agonism assay) or inhibition (antagonism assay) according to the equation: Y = Bottom of dose-response curve + (Top of dose response curve-Bottom)/{1+10\^\[(LogIC~50~-X) × HillSlope\]} using a least squares (ordinary) fit with a maximum of 1000 iterations.

The antagonism assay was considered negative when there was \< 20% inhibition (relative induction ≥ 80%) at all doses, which was a cut-off suggested by the assay vendor and used to interpret ERα CALUX data ([@kfy245-B30]). Where the antagonism assay showed inhibition of at least 20% (relative induction ≤ 80%) the specificity control assay described above was performed for all test substances with the exception of hydroxyflutamide, which is a well-known specifically acting anti-androgen. For specifically acting anti-androgens there is a clear right shift in the dose-response between the non-saturating and the saturating concentration of DHT (see flutamide curves in [Figure 2](#kfy245-F2){ref-type="fig"}). Where this right shift was observed, or where the test substance no longer showed an inhibition of luciferase induction at the saturating concentration, this provided evidence that the decrease in relative induction at the non-saturating concentration was reversible and test substance was considered to be a specifically acting anti-androgen. However, if the dose-response remained the same the inhibition of luciferase was considered to be due to a non-specific effect, and the test substance was not considered to be a specifically acting anti-androgen. This was evaluated for at least 3 individual replicates.

EXPOSURE: ACTIVITY PROFILING
============================

Exposure: activity profiling was performed using a similar approach to that proposed for estrogenic responses ([@kfy245-B11][@kfy245-B10]). First, a suitable comparator was identified from the dietary components tested in the assay as a substance which showed a specific effect on the AR signaling pathway. The only dietary components that showed these characteristics were resveratrol and 3,3-diindolylmethane (DIM). DIM has previously been proposed as a promising dietary comparator for exposure to anti-androgens ([@kfy245-B11][@kfy245-B10]), and because the dose-response for DIM was more typical of a AR antagonist this was selected as the comparator (see Results section). An exposure: activity ratio was therefore calculated for DIM using the predicted total plasma exposure and *in vitro* anti-androgenic activity data. The IC~50~ was selected as it is considered the most appropriate metric to use in EAR calculations ([@kfy245-B10]): $$\text{EAR(unitless)~} = \frac{\text{Exposure~(plasma~exposure~in~µM)}}{\text{Activity~(IC}_{\text{5}0}\text{µM)}}$$

Because DIM exposure varies widely between individuals ([@kfy245-B19]), to give a representation of this variability, EARs were calculated using PBBK (physiologically based biokinetic) modeling for individuals showing high, mean, and low plasma exposures. A sub-population of concern with regards to perturbations in AR signaling is pregnant women, due to the risk of serious and irreversible harm associated with blockade of AR signaling during the fetal masculinization programming window ([@kfy245-B27]). We therefore modeled plasma exposure to females of childbearing age to provide the benchmark EAR.

EARs were calculated for the remaining test substances using the same equation. Where exposure data allowed, EARs for the remaining test substances were also calculated to describe the variability in human exposures. Where the dose-response was not sufficiently well described to confidently set the IC~50~, the concentration at which the response of the test substance equalled 50% of the maximum response of the reference standard (flutamide) was calculated and this value (termed the PC~50~) was used instead ([@kfy245-B30]). EARs were also calculated using AR CALUX^®^ IC~50~ values found in the literature for the anti-androgens *p*,*p*′-DDE, vinclozolin, methoxychlor, HPTE, and BPA ([@kfy245-B38]; [@kfy245-B39]; [@kfy245-B44]).

Dietary comparator ratios (DCRs) were calculated based on the ratio of the EAR for the test substance to the EAR for DIM: $$\text{DCR~} = \,\frac{\text{EAR}_{\text{Test~substance}}}{\text{EAR}_{\text{DIM}}}$$

In considering these comparisons it should be noted that some of the EARs were calculated using serum or plasma exposure measured in males, most notably flutamide and hydroxyflutamide. The purpose of including these substances was to illustrate 'high risk' DCRs, encompassing exposures that are intended to completely suppress AR signaling in humans (in the case of flutamide and its active metabolite hydroxyflutamide, adult males suffering from prostate cancer). Complete suppression of AR signaling following flutamide administration to pregnant rats has been shown to cause serious and irreversible adverse effects on their male offspring ([@kfy245-B27]). It is therefore considered that the DCRs determined for flutamide and hydroxyflutamide would indicate a high probability of impacting AR signaling in all populations including pregnant women.

Variability in DCR was expressed where data allowed the range of variability in human exposure to be characterized by calculating DCRs for the highest EAR~Test\ substance~/the lowest EAR~DIM~, the mean (or where appropriate median) EAR~Test\ substance~/the mean EAR~DIM~ and the lowest EAR~Test\ substance~/the highest EAR~DIM~. Where the range of variability was not available (eg, for flutamide and hydroxyflutamide) the variability in DCR was expressed by calculating this parameter for the mean EAR~Test\ substance~/the lowest, mean, and highest EAR~DIM~ (see [Supplementary Materials](#sup1){ref-type="supplementary-material"} for more detail and all calculations).

EXPOSURE ASSESSMENT
===================

It was only necessary to perform exposure assessments for those test substances showing anti-androgenic activity in the AR CALUX^®^ assay, because EARs cannot be calculated for substances showing no activity. The human plasma or serum exposures that were used in the EAR calculations were either found in the literature or generated using a PBBK model. References used to provide the exposure data are summarized in [Table 1](#kfy245-T1){ref-type="table"}, and full details of the exposure data or predictions used and all EAR and DCR calculations are provided in the [Supplementary Material](#sup1){ref-type="supplementary-material"}. Table 1.Exposure Data Used in Calculation of EARs (See [Supplementary Materials](#sup1){ref-type="supplementary-material"} for All Exposure Data and Predictions Used)Substance (Description)Exposure Data DescriptionReferenceDIM (metabolite of glucobrassicin, widely consumed in cruciferous vegetables)PBBK model predicting DIM plasma exposure (C~max~) following consumption of 50 g brussels sproutsReported here (see [Supplementary Materials](#sup1){ref-type="supplementary-material"})Resveratrol (present in skin of berries including grapes)Human pharmacokinetic data describing C~max~ following exposure to 25 mg resveratrol. This represents a high level of dietary intake ([@kfy245-B31]) but is well below the level used as a food supplement ([@kfy245-B33]).[@kfy245-B22]Flutamide and hydroxyflutamide (prostate cancer drug and its active metabolite)Human pharmacokinetic data describing C~max~ at steady state following repeated exposure therapeutic dose of flutamide[@kfy245-B32]BPA (industrial chemical)Predicted plasma concentration at steady state (C~ss~) based on kinetic modeling at human exposures of 4 µg/kg/day (the Tolerable Daily Intake \[TDI\] set by European Food Safety Authority \[EFSA\])[@kfy245-B46]Vinclozolin (plant protection product)Predicted plasma C~ss~ based on kinetic modeling at human exposures of 25 µg/kg/day (the Reference Dose \[RfD\] set by the US Environmental Protection Agency \[EPA\])[@kfy245-B46]Methoxychlor (plant protection product)Predicted C~ss~ based on kinetic modeling at human exposures of 5 µg/kg/day (the RfD set by the U.S. EPA)[@kfy245-B46]HPTE (metabolite of methoxychlor)Predicted C~ss~ based on kinetic modeling at human exposures of 5 µg/kg/day (the RfD for methoxychlor set by the U.S. EPA)[@kfy245-B46]*p*,*p*′-DDE (metabolite of the insect control agent DDT)Human biomonitoring describing serum levels of populations exposed in the United States in the 1950s and 1960s and a population exposed in a DDT-sprayed area in South Africa in 2003--2005[@kfy245-B26], [@kfy245-B12], and [@kfy245-B6]Bakuchiol (risk assessment case study)PBBK model predicting bakuchiol plasma exposure (C~max~) following once-daily use of a body lotion or a shampoo containing this substance at 0.5% (hypothetical products)Reported here (see [Supplementary Materials](#sup1){ref-type="supplementary-material"})

No exposure assessment was performed for AG, which was negative in the AR CALUX^®^ assay (see AR CALUX^®^ Assay section).

RESULTS
=======

AR CALUX^®^ Assay
-----------------

A summary of the results for AR CALUX^®^ assays is shown in [Table 2](#kfy245-T2){ref-type="table"}. None of the test substances showed a positive response in the agonism assay, whereas in each experiment DHT gave a consistent positive response with very little variability between experimental replicates. Table 2.AR CALUX® Assay ResultsSubstanceAgonism AssayAntagonism AssayAntagonism Assay IC~50~Positive or Negative (+/−)(µM)[^a^](#tblfn3){ref-type="table-fn"}FlutamideNT+0.876HydroxyflutamideNT+0.0282Genistein---−---Resveratrol---+21.7Rutin hydrate---−---Quercetin hydrate---−---DIM---+1.27Bakuchiol---+2.85[^b^](#tblfn4){ref-type="table-fn"}AG---−---[^1][^2][^3][^4]

As expected, flutamide was less potent in the antagonism assay than was its active metabolite 2-hydroxyflutamide ([Table 2](#kfy245-T2){ref-type="table"}, [Figure 1](#kfy245-F1){ref-type="fig"}).

![Androgen receptor antagonism results for hydroxyflutamide, mean data from 3 independent experiments, error bars ±SEM.](kfy245f1){#kfy245-F1}

Quercetin, rutin, and AG gave negative results in the antagonism assay, because in all 3 replicates there was less than a 20% reduction in relative luciferase induction at any concentration. Flutamide (which was run on all plates) showed the expected antagonistic response.

Genistein met the criteria to progress to a specificity control assay (20% reduction in relative induction). A specificity control assay was therefore performed to ensure this was due to a specific effect on the AR signaling pathway, which showed the reduction in relative induction of luciferase for flutamide was reversible in the presence of a saturating concentration of DHT for all 3 replicates ([Figure 2](#kfy245-F2){ref-type="fig"}). However, for genistein the dose-response showed no right shift in the presence of a saturating concentration of DHT. This indicates that the reduced luciferase expression was due to an effect unrelated to the AR signaling pathway, and genistein was not acting as a specific AR antagonist in this assay, highlighting the value of the specificity control assay.

![Androgen receptor antagonism and specificity control results for genistein, DIM, resveratrol, and bakuchiol. Each graph represents mean data from at least 3-independent experiments, error bars ± SEM. No model curve shown for bakuchiol at DHT 100×EC50 as chosen model did not meet goodness of fit criteria.](kfy245f2){#kfy245-F2}

Resveratrol showed a clear reduction in relative induction, and the dose-response was so steep that additional experiments were performed to ensure the full dose-response could be described ([Figure 2](#kfy245-F2){ref-type="fig"}). The steep dose-response curve for resveratrol did complicate data interpretation, but overall the data indicated that the effect on relative induction was considered at least partly reversible with a slight increase in IC~50~ from 2.17 × 10^−5^ to 2.73 × 10^−5^ M.

DIM showed a clear reduction in relative luciferase induction, meeting the criteria for specificity control testing. Addition of the saturating concentration of DHT clearly shifted the dose-response to the right ([Figure 2](#kfy245-F2){ref-type="fig"}), increasing the IC~50~ from 1.27 × 10^−6^ to 7.50 × 10^−6^ M, indicating the effect on luciferase expression was reversible and that DIM was acting as a potent and specific AR antagonist. DIM was therefore selected as the dietary comparator, primarily because the dose-response was more clearly typical of an AR antagonist than was the dose-response for resveratrol. In addition, although some studies have shown a health protective effect of either resveratrol or red wine ([@kfy245-B9]), the safety of liberal consumption of crucifers is less contentious than consumption of red wine. The assumption is that although DIM is a potent anti-androgen, normal dietary consumption of cruciferous vegetables is not expected to cause adverse effects in humans relating to disturbance of AR signaling.

Bakuchiol showed a clear dose-dependent reduction in relative luciferase induction ([Figure 2](#kfy245-F2){ref-type="fig"}), with the 2 highest concentrations resulting in \> 20% reduction. GraphPad was unable to make a full dose-response fit to the bakuchiol data, meaning a reliable IC~50~ for bakuchiol could not be calculated. Additional (higher) concentrations of bakuchiol would be necessary to fully describe the dose-response, but because the highest concentration of 3 µM was close to the cytotoxic dose range a higher dose was not tested, and instead a mean PC~50~ value across all 6 replicates was calculated ([Table 2](#kfy245-T2){ref-type="table"}). The relationship between the relative induction values of bakuchiol at the non-saturating concentration of the ligand (DHT) with the saturating concentration confirmed that addition of the saturating concentration reversed the effect on luciferase induction in all 6 replicates ([Figure 2](#kfy245-F2){ref-type="fig"}). Therefore, the specificity control assay did indicate that the reduction in relative luciferase induction was a specific effect on AR-mediated signaling.

*In Vitro* to *In Vivo* Extrapolation
-------------------------------------

A comparison of the *in vitro* points of departure (IC~50~ or for bakuchiol PC~50~) including upper and lower 95% CI where this could be calculated, and the *in vivo* exposure data or predictions are shown in [Figure 3](#kfy245-F3){ref-type="fig"}. For only 2 substances were the predicted or measured systemic exposures greater than the *in vitro* points of departure: hydroxyflutamide and *p*,*p*′*-*DDE exposure values from one study ([@kfy245-B6]). For all other case substance exposures, the *in vitro* point of departure was greater than the predicted or measured systemic exposure.

![Comparison of AR CALUX® point of departure (IC50 or PC50) and measured or predicted serum or plasma exposure. Circles represent IC50 values, triangles represent serum, or plasma exposure. Dietary comparator (DIM) in blue, case study ingredient (bakuchiol) with hypothetical exposure scenarios in red. Bakuchiol uses PC50 rather than IC50. For exposure data, where values for uncertainty (eg, 95%CI) or variability (eg, percentile exposure) were published these are as described in the [Supplementary Materials](#sup1){ref-type="supplementary-material"}.](kfy245f3){#kfy245-F3}

Dietary Comparator Ratios (DCRs)
--------------------------------

Calculations showing the individual EARs and corresponding DCRs are detailed in the [Supplementary Materials](#sup1){ref-type="supplementary-material"}, and a comparison of the resulting DCRs is shown in [Figure 4](#kfy245-F4){ref-type="fig"}. Due to its low bioavailability, the mean DCR for DIM was the lowest calculated. The DCR range for resveratrol, vinclozolin, BPA, and methoxychlor overlapped with the DCR range for DIM. Aside from the shampoo case study (see Case Study Risk Assessment section), all other substance exposures provided DCRs that did not overlap with the range for DIM, with hydroxyflutamide providing the highest value, with a mean DCR of 594 000.

![Dietary comparator ratios (DCRs). Dietary comparator (DIM) in blue, case study ingredient (bakuchiol) with hypothetical exposure scenarios in red.](kfy245f4){#kfy245-F4}

Case Study Risk Assessment
--------------------------

Once we had determined the DCRs for the substances described above, we considered how this approach could be used to assist safety decision making using a hypothetical case study, the use of bakuchiol or AG in a body lotion or shampoo at 0.5%. In a safety risk assessment for a real consumer product other MIEs and pathways would also need to be considered, but because the purpose of this case study was to evaluate the DCR methodology we concentrated solely on AR antagonism.

AG was negative in both the agonism and antagonism assay and was therefore not taken forward as the subject of the risk assessment case study. The positive result in the AR CALUX^®^ (antagonism) assay for bakuchiol was clear, although this substance was amongst the least potent anti-androgens tested ([Table 2](#kfy245-T2){ref-type="table"}; [Figure 3](#kfy245-F3){ref-type="fig"}). The exposure assessment based on worst-case consumer exposure to 0.5% bakuchiol in a body lotion or shampoo predicted plasma exposure for adult females of 0.320 and 0.00234 µM, respectively. The *in vitro* point of departure (in this case the PC~50~) was below these predicted human exposure levels. To further put this margin into context, the DCRs for bakuchiol in body lotion and shampoo were calculated ([Figure 4](#kfy245-F4){ref-type="fig"}). The mean DCR for bakuchiol body lotion was 151, which is in a similar range to the *p*,*p*′*-*DDE exposures included in the benchmarking. The mean DCR for bakuchiol at 0.5% in shampoo was 2.34.

DISCUSSION
==========

Using the EAR for DIM as a comparator with other substances by calculating their DCR is a pragmatic risk ranking approach, whereby DCRs below 1 provide strong assurance that adverse effects in humans relating to perturbations in AR signaling are very unlikely for that exposure scenario. It is important to note that a DCR greater than 1 does not necessarily indicate high risk. If that were the case consumption of anything more than 50 g brussels sprouts would be considered by this approach to be harmful (see [Supplementary Material](#sup1){ref-type="supplementary-material"} for DIM exposure modeling). However, the closer the DCR is to the anti-androgenic drug flutamide and its active metabolite hydroxyflutamide, the greater the risk. This is because systemic exposure to hydroxyflutamide following therapeutic use of flutamide is intended to completely supress AR signaling, and as such significant health effects relating to AR signaling would be expected in any population exposed to these levels. Use of DCRs for risk ranking requires careful consideration of the mode of action of the substance being risk assessed and how this compares with the dietary comparator.

The range of DCRs for resveratrol, BPA, vinclozolin, and methoxychlor overlapped with the range of DCRs for DIM. The DCRs for the methoxychlor metabolite HPTE were outside the range of DCRs for DIM. The exposure assessments for BPA, vinclozolin, and methoxychlor were based on the assumption that the reference dose or TDI for these substances was ingested, and HPTE was based on the assumption that the reference dose of methoxychlor was ingested and completely converted to HPTE, which is clearly worst-case. Because the reference doses or TDI for BPA, vinclozolin, and methoxychlor were set to be protective of all adverse effects on human health (including those relating to AR signaling in both adults and the developing fetus) although some were \> 1, the DCR for these substances are also likely to represent a 'region of safety.' The exposure assessment for resveratrol was based on consumption of 25 mg/day. Although some have described this as representing a moderate intake of red wine ([@kfy245-B42]), depending on the variety it is possible that well over 600 ml of red wine may need to be consumed to reach this level of intake ([@kfy245-B31]). The DCR approach suggests that even at this level of intake the resveratrol present in the wine is unlikely to have any significant AR-mediated adverse effects.

The progression from an MIE to an adverse outcome is dependent on the magnitude and duration of the initial interaction, and transient activation of an MIE or a key event may not result in an adverse outcome. It is therefore important to understand these dose-dependent transitions (or 'tipping points') to ensure the risk assessment is relevant to the protection of human health (Slikker *et al.*, [@kfy245-B36]a,b). From our data it is not possible to accurately determine a tipping point, that, if reached would indicate a transition from adaptation to adversity. When considering whether it was feasible to set a tipping point, we investigated whether exposures to *p*,*p*′*-*DDE, the active metabolite of the organochlorine pesticide DDT could provide some useful insights. Exposures to DDT and *p*,*p*′*-*DDE have been associated with a number of adverse health effects, including adverse developmental/reproductive effects relating to the AR signaling pathway such as cryptorchidism and hypospadias, and numerous epidemiology studies have been performed examining the link between serum *p*,*p*′*-*DDE levels and adverse outcomes ([@kfy245-B13]). Case-control studies investigating the relationship between exposure to *p*,*p*′*-*DDE and birth defects which were based on data collected in the United States in the 1950s and 1960s with median maternal serum levels in the control groups of 34.3 µg/l ([@kfy245-B26]) or 43 µg/l ([@kfy245-B12]) have failed to show a conclusive association between exposure and hypospadias or cryptorchidism. Studies performed in areas where DDT is still used for malarial control have shown some associations between adult (male) serum levels of *p*,*p*′*-*DDE and sperm quality/quantity. For instance, in one cross-sectional study of 311 adult men from a DDT-sprayed area in South Africa with a median serum *p*,*p*′*-*DDE level of 697 µg/l, exposure was associated with impaired sperm motility, sperm cytoplasmic droplets, reduced ejaculate volume, and oligozoospermia ([@kfy245-B6]). We calculated EARs and DCRs for these *p*,*p*′*-*DDE exposure scenarios using published AR CALUX^®^ data ([@kfy245-B39]) to see how they compared, and only the exposure data from the high exposure study in South Africa ([@kfy245-B6]) exceeded the IC~50~ for *p*,*p*′*-*DDE. When interpreting these data, it is important to remember that the case-control studies reflected maternal serum exposure, whereas the cross-sectional study reflected adult male serum exposure. Therefore, it is not appropriate to use these data to define a transition from 'endocrine activity' to 'endocrine disruption.' They are however informative for the purposes of risk ranking. It should be noted that although most studies investigating the effects of lower exposures to DDT or *p*,*p*′*-*DDE (eg, recent studies in developed countries) do not show any associations between either maternal or adult male exposure and birth defects or impaired sperm, some have shown an association. For example, one well conducted study has shown an association between maternal serum exposures of around 1 ng/ml and hypospadias ([@kfy245-B34]). Whether the association seen in that study was due to *p*,*p*′*-*DDE exposure is not clear, especially given the large number of studies at similar exposure levels which have not found associations ([@kfy245-B15]; [@kfy245-B21]). These include investigations into the potential for long-term effects of *in utero* exposure to *p*,*p*′*-*DDE. For example, in a well-designed study 176 male offspring from a Danish cohort of women, there was no relationship between maternal *p*,*p*′*-*DDE levels and long term consequences on male reproductive health with median maternal serum levels of 8 pmol/ml (2.54 ng/ml) ([@kfy245-B41]). Given the contentious nature of potential low dose effects we have focused our evaluation on populations exposed to high levels of *p*,*p*′*-*DDE. This is in line with the conclusions of the US Agency for Toxic Substances and Disease Registry, which concluded that if a relationship between *p*,*p*′*-*DDE exposure and adverse reproductive/developmental outcomes in humans exists, it is found in populations exposed to high DDT concentrations ([@kfy245-B7], [@kfy245-B8]).

AG was negative in the AR CALUX^®^ assay, which was surprising given the existing *in vitro* and *in vivo* data. Although several rat male fertility studies on either *Andrographis paniculata* or AG have shown no adverse effects ([@kfy245-B3]; [@kfy245-B14]), others have shown marked adverse effects on fertility ([@kfy245-B1]; [@kfy245-B2]; [@kfy245-B35]). AG is also reported to affect androgen signaling in prostate cancer cell lines ([@kfy245-B25]), suggesting an ability to reduce AR expression at the transcriptional level, inhibit nuclear translocation of AR, inhibit the formation of stabilizing complexes with the co-chaperone Hsp90, slow the growth of C4-2 prostate cancer cells, and induce apoptosis. This was the reason for including AG in this evaluation. The lack of response seen in our study likely reflects differences between AR CALUX^®^ cells and C4-2 cells, which were originally derived from LNCaP prostate cancer cells ([@kfy245-B47]). Given these conflicting data, logical next steps for the evaluation of AG include assessing the reproducibility of the findings in C4-2 cells and assessing whether metabolism of AG could account for differences between these cell types.

Because different assays may provide different AC~50~ or IC~50~ values for the same test substance, it is important to ensure that all data used for a specific mode of action are comparable, ie, produced in the same assay system, and that dose-response information from that system are reproducible. The available pre-validation data on the AR CALUX^®^ assay shows that the average IC~50~s were within a factor of 3 between 2 laboratories ([@kfy245-B40]), and in our study where the same substance (flutamide) was used our IC~50~ value was similar to the published range. In the pre-validation study the average IC~50~ values for flutamide following 6 or 7 experiments were 0.399 and 0.516 µM for laboratory 1 and laboratory 2 respectively, and our IC~50~ value was 0.876 µM.

Although the *in vitro* point of departure for bakuchiol (in this case the PC~50~) was below the predicted human exposure levels following use in both shampoo and body lotion, it was close for body lotion (approximately 10-fold below). The DCR for bakuchiol at 0.5% in body lotion was in a similar range to the DCRs calculated for the *p*,*p*′*-*DDE exposures included in the benchmarking, and the DCR for bakuchiol at 0.5% in shampoo overlapped with range of DCRs for DIM. With the current predictions, exposure to bakuchiol at 0.5% in a body lotion suggests the possibility that AR signaling may be perturbed in consumers, indicating the need for a more detailed evaluation in higher-tier models. Alternatively, exposure to bakuchiol at 0.5% in a shampoo appears low risk for this mode of action.

Sources of Uncertainty
----------------------

As with any risk assessment, there are several uncertainties with this approach that need to be understood to enable informed safety decision making. These include the reliance on predicted plasma exposures for the dietary comparator DIM. However, as described in the [Supplementary Materials](#sup1){ref-type="supplementary-material"}, sufficient data were available to build a model which correlated well with measured human plasma levels following administration of a known quantity of absorption-enhanced DIM and confidence that these predictions are suitable for the purpose of this investigation is high.

The skin penetration parameters used in the bakuchiol PBBK model were all predicted, and no human kinetic data were available to assess the performance of the model, meaning confidence in these predictions is much lower than confidence in the DIM model (see [Supplementary Materials](#sup1){ref-type="supplementary-material"}). Further data generation, especially *in vitro* skin penetration, plasma protein binding, and hepatocyte clearance would refine the exposure model, and obtaining human kinetic data to evaluate the performance of the model would greatly increase confidence in the model predictions.

In this study, plasma C~max~ was used as the measure of exposure. Some substances, like resveratrol and DIM are very rapidly cleared, whereas others, like *p*,*p*′*-*DDE are very persistent. This is significant because clearance of anti-androgens is an important determinant in their efficacy ([@kfy245-B20]). DCR values must therefore be considered alongside the overall pharmacokinetic profile of the substance being evaluated. In other words, substances in the 'region of safety' which are much more persistent than DIM and the other benchmark substances may require further evaluation.

In [Figure 3](#kfy245-F3){ref-type="fig"}, we were able to characterize the level of uncertainty or variability for some but not all bioactivity or exposure data. As described in the [Supplementary Materials](#sup1){ref-type="supplementary-material"}, a measure of uncertainty or variability was available in the exposure data for all test substances apart from flutamide, hydroxyflutamide, and resveratrol. A measure of uncertainty or variability was presented in the bioactivity data we generated, because in [Figure 3](#kfy245-F3){ref-type="fig"} the best-fit and lower and upper 95% confidence intervals (CI) of the IC~50~ were presented. However, because there was very little variability in the data the error bars are generally not visible on the logarithmic scale. The lack of 95% CI for the published AR CALUX^®^ data is therefore not considered to be a significant contributor to uncertainty within the risk assessment.

A number of anti-androgenic substances, including flutamide, methoxychlor, and vinclozolin, have metabolites which are more potent than the parent. This exposes a potential weakness in the way we performed the AR CALUX^®^ assay, ie, without metabolic activation. This refinement has been described ([@kfy245-B29]) and would be a useful additional test to include to provide further information, firstly on whether a metabolite of AG could cause transcriptional effects in the AR pathway, and also whether a metabolite of bakuchiol could be more active than its parent.

The *in vitro* to *in vivo* comparisons we have performed were based on total concentration rather than free concentration in test media and plasma, which in general are considered a more appropriate dose metric for *in vitro* to *in vivo* extrapolation ([@kfy245-B23]). Therefore, any comparison for a substance that shows different kinetics *in vitro* and *in vivo* (eg, those that are extensively bound to plastic or serum) will be flawed. A lot of the substances we tested would be expected to be extensively bound both *in vitro* and *in vivo.* We considered the physico-chemical properties of our test and reference substances, and in particular our key comparator, DIM. Based on this evaluation we determined that *in vitro* and *in vivo* exposures to free DIM (and the other test substances) are likely to be within one order of magnitude of their nominal concentration, although analytical determination of free DIM in the assay medium and plasma protein binding would provide further confirmation of this.

CONCLUSION
==========

Historically, reporter gene assays for endocrine modes of action have been used to prioritize chemicals for follow-up in subsequent *in vivo* studies, to assess whether the endocrine activity seen *in vitro* translates to an *in vivo* adverse effect and to set a point of departure (eg, a no-observed-adverse-effect level) for risk assessment. One of the objectives of this study was to investigate use of exposure data at an earlier step in this paradigm to prevent the need to generate animal data on chemicals with low activity relative to their associated human exposures. We found that the use of DCRs is a pragmatic approach which allows novel chemical exposures (as described by the bakuchiol case study) to be put into context against normal dietary exposure to anti-androgens such as DIM, and against other anti-androgenic chemicals. The DCR approach may have utility for other modes of action where appropriate comparators can be identified.

SUPPLEMENTARY DATA
==================

[Supplementary data](#sup1){ref-type="supplementary-material"} are available at Toxicological Sciences online.

Supplementary Material
======================

###### 

Click here for additional data file.

The authors would like to thank Andrew White, David Sanders, Beate Nicol, and Carl Westmoreland (Unilever) and Lydia Jonker, Harrie Besselink, and Peter Behnisch (BioDetection Systems) for their technical advice and helpful insights. The authors declare there are no conflicts of interest.

FUNDING
=======

This work was funded by Unilever as part of Unilever's ongoing effort to develop new ways of assuring consumer safety.

[^1]: All values presented to 3 significant figures.

[^2]: NT, not tested.

[^3]: Best-fit IC~50~ from at least 3-independent experiments at a non-saturating concentration of DHT.

[^4]: PC~50~ value presented as a reliable IC~50~ value could not be obtained from the dose-response.
